

Special Issue

Muscular Dystrophies: Pathophysiology and Therapy

Message from the Guest Editors

This Special Issue, "Muscular Dystrophies: Pathophysiology and Therapy", will focus on the pathophysiological mechanisms underlying muscular dystrophies, new animal models and methodological approaches for studying muscle dysfunction/recovery, as well as the development of innovative therapeutic strategies and ongoing clinical trials. Therapeutic strategies that address the root cause of these diseases are currently being developed for a handful of muscular dystrophies, including virus-based gene therapy and antisense drugs. In this context, the activation of the host immune system against the transgene or viral capsid, the route of administration and the accurately targeted tissue, in order to achieve the restoration of fully functional muscle in patients, remains a challenge. Therefore, strategies that aim to rescue altered proteins, as well as animal models and methodologies, must be optimized. These must be improved to achieve robust readouts, allowing the validation of treatment efficacy in clinical trials. This Special Issue is open to research studies, ranging from basic to preclinical approaches, and will also cover original articles and reviews.

Guest Editors

Dr. France Piétri-Rouxel

Dr. Sestina Falcone

Prof. Dr. Edoardo Malfatti

Deadline for manuscript submissions

closed (10 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/111090

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).